Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vamifeport in adults with HFE-related hereditary hemochromatosis
NL-OMON61056Phase 2Not yet recruiting
- Sponsor
- CSL Behring
- Start
- Feb 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of vamifeport in hereditary hemochromatosis (HH), sponsored by CSL Behring. Primary endpoint: Change from baseline in MRI-based liver iron concentration. Planned start Feb 2026; status: not yet recruiting.
02
Drugs
vamifeport
03
Conditions
hereditary hemochromatosis (HH)
Beyond the preview
Go deeper on NL-OMON61056.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61056.